(1), but it is also superior to surgery in high-risk patients (2) . The primary endpoint for the pivotal trials of TAVR (1, 2) has been all-cause mortality, but other events reflecting the safety of the procedure, such as vascular complications and bleeding, have also been assessed.
As with other endovascular procedures, these events after TAVR are associated with a significant increase in adverse outcomes such as renal failure and mortality (3) . The early iterations of TAVR devices used very large bore sheaths (up to 24 F), which likely influenced the risk of bleeding and vascular complications in the elderly and frail patients included in the trials. Moreover, the anticoagulant agent used in the procedures was 7,000 to 10,000 units of unfractionated heparin (UFH). In this context, hemorrhagic complications in the pivotal TAVR trials occurred with a relatively high frequency. Strategies to mitigate the risk of these complications are a priority in the TAVR space.
Currently available lower profile aortic valve delivery sheaths reduce arterial trauma and likely lower the incidence of bleeding. Another approach, however, is to manage procedural antithrombotic therapy in a way that makes the procedure safer. An obvious choice in this regard is bivalirudin, a direct thrombin inhibitor with a short half-life, which has been asso- as Guest Editor for this paper.
UFH plus GPI; however, compared with UFH alone or GPI added to bivalirudin, this safety advantage is no longer present (6) . What accounts for these differences, and how does it relate to procedural strategies for TAVR?
It is important to recognize that procedural medi- 
